The decision delays regulatory clearance for Bharat Biotech’s proposed phase III trial of MTBVAC, one of the world’s most advanced tuberculosis vaccine candidates and a potential successor to the century-old BCG
Regulator flags gaps in Bharat Biotech’s TB vaccine trial
